Status:
COMPLETED
The Absorption of Magnesium Oxide Compared to Citrate in Healthy Subjects
Lead Sponsor:
Sheba Medical Center
Conditions:
Healthy Subjects
Hypomagnesemia
Eligibility:
All Genders
20-70 years
Phase:
PHASE4
Brief Summary
The magnesium food content in the Western world is consistently reducing. Hypomagnesemia is common in hospitalized patients, especially in the elderly with coronary artery disease (CAD) and/or those w...
Detailed Description
Two oral preparations of magnesium are available in Israel: 1. Magnesium Diasporal (magnesium citrate, elemental magnesium 98.6 mg), PROTINA GMBH, ISMANING, Germany 2. Magnox 520 TM (magnesium oxide,...
Eligibility Criteria
Inclusion
- Age 20-70 years
- Healthy subjects
Exclusion
- Chest pain
- Diabetes mellitus
- Documented coronary artery disease
- Asthma or any lung disease
- Chronic diarrhea
- Chronic renal failure (serum creatinine\> 3 mg/dL)
- Hypo or hyperthyroidism
- Heart failure
- On any chronic therapy/medications
- Malabsorption
- AV block
- Pacemaker
- Any malignancy
- Obesity \> 30 kg/m2 body mass index
- Smokers
- Pregnancy
- Alcohol or drug abuse
- Any chronic inflammation
- Refuse to sign inform consent
Key Trial Info
Start Date :
January 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2011
Estimated Enrollment :
41 Patients enrolled
Trial Details
Trial ID
NCT00994006
Start Date
January 1 2010
End Date
March 1 2011
Last Update
May 4 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Leviev Heart Center, Chaim Sheba Medical Center
Tel Hashomer, Ramat Gan, Israel, 52621